Targeting eosinophils: severe asthma and beyond

Drugs in Context
Marco CaminatiGianenrico Senna

Abstract

Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and eliciting a NK cell-mediated antibody-dependent cellular cytotoxicity against eosinophils. Eosinophilic inflammation represents the common pathophysiological background of several conditions, providing the rationale for the use of the same biologics beyond asthma. Although with different evidence grade, from clinical trials to case reports, anti-IL-5 biologics have been investigated in eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. However, non-negligible differences between asthma and other eosinophilic diseases, particularly in eosinophils homing (blood and/or tissues), target organs and thus clinical features, probably account for the different response to the same drug in different clinica...Continue Reading

Citations

Sep 29, 2020·Journal of Asthma and Allergy·Francesco MenzellaNicola Facciolongo
Mar 4, 2021·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Ana Isabel Enríquez-RodríguezPere Casan Clara
Mar 5, 2021·International Forum of Allergy & Rhinology·Alexander L SchneiderBruce K Tan
May 1, 2021·Cells·Meenakshi Tiwary, Amali E Samarasinghe
Jul 31, 2021·Expert Opinion on Biological Therapy·Konstantinos KatsoulisStelios Loukides

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02452190
NCT02501629
NCT02559791
NCT02947945
NCT03010436
NCT03450083
NCT03627286

Software Mentioned

SIROCCO
COSMOS
CALIMA

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.